Facioscapulohumeral muscular dystrophy’s game of homeodomains: therapy wants a biomarker as a sword wants a whetstone

This scientific commentary refers to ‘The FSHD muscle-blood biomarker: a circulating transcriptomic biomarker for clinical severity in facioscapulohumeral muscular dystrophy’, by Banerji et al. (https://doi.org/10.1093/braincomms/fcad221).

Detalles Bibliográficos
Autores principales: Kyba, Michael, Bosnakovski, Darko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Scientific Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507743/
https://www.ncbi.nlm.nih.gov/pubmed/37731901
http://dx.doi.org/10.1093/braincomms/fcad235
Descripción
Sumario:This scientific commentary refers to ‘The FSHD muscle-blood biomarker: a circulating transcriptomic biomarker for clinical severity in facioscapulohumeral muscular dystrophy’, by Banerji et al. (https://doi.org/10.1093/braincomms/fcad221).

Ejemplares similares